NEW YORK, Aug. 22 – Genomics Collaborative said on Wednesday that it has signed up its first five biopharmaceutical companies to access its newly launched database of DNA, sera, and tissue samples.
Pharmacia Corporation, GlaxoSmithKline, and Exelixis Corporation were three of the five companies that Genomics Collaborative said in a statement were new clients. A company spokesman would not disclose the names of the two remaining firms, but confirmed that they are based in the US.
The companies will gain access to Genomics Collaborative’s GCI Access database to research matched case-to-control populations comprising various inflammatory, cardiovascular, and metabolic disease states, the company said. The product holds data from more than 100,000 patients.
“We are encouraged by the pharmaceutical industry’s enthusiastic and rapid response to GCI Access,” Michael Pellini, CEO of Genomics Collaborative, said in a statement. “As the number of global pharmaceutical product launches increase so does the need to access well-characterized patient clinical data. …”
Genomics Collaborative, a privately held functional genomics company based in Cambridge, Mass., will present its Access product at the Institute for Genomic Research’s Genome Sequencing and Analysis Conference in October.
A company spokesman would not disclose the price of the Access database, which was launched in June.
Earlier this month, Genomics Collaborative and ActivX Biosciences initiated a joint program to identify proteins with potential as drug targets for colon cancer.
Under this deal , Genomics Collaborative will supply colon cancer cells to ActivX for analysis. ActivX, meanwhile, will screen those cells for proteins associated with colon cancer by using its platform for synthesizing chemical probes that bind with active sites specific to whole protein families.